Modelled DT Structure
Method: multi-sequence alignment based machine learning
Detail: Structure Info
Drug Transporter (DT) Information
| General Information of DT | |||||
|---|---|---|---|---|---|
| DT ID | DTD0318 | ||||
| Gene Name | SLC36A1 | ||||
| Protein Name | Proton-coupled amino acid transporter 1 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| TCDB ID | |||||
| 3D Structure |
|
||||
| Synonyms | LYAAT1; PAT1; Proton/amino acid transporter 1; SLC36A1; Solute carrier family 36 member 1; TRAMD3; hPAT1 | ||||
| DT Family | Amino Acid/Auxin Permease (AAAP) Family ; | ||||
| Function | This tranporter has a pH-dependent electrogenic transport activity for small amino acids such as glycine, alanine and proline. Besides small apolar L-amino acids, it also recognizes their D-enantiomers and selected amino acid derivatives such as gamma-aminobutyric acid. | ||||
| Disease(s) | Epilepsy [ICD-11:8A6Z] | ||||
| Insomnia [ICD-11:7A0Z] | |||||
| Nutritional deficiency [ICD-11:5B7Z] | |||||
| Peripheral T-cell lymphoma [ICD-11:2A90.C] | |||||
| Tuberculosis [ICD-11:1B1Z] | |||||
| Endogenous Substrate(s) | H+ | ||||
| Variability Data of This Drug Transporter (DT) | |||||
|
Regulatory Variability Data of This DT (VARIDT 4.0) |
|||||
|
(α) Tissue Distribution Level of Proton-coupled amino acid transporter 1 |
|||||
|
(β) Cell Distribution Level of Proton-coupled amino acid transporter 1 |
|||||
|
(γ) Organelle Distribution Level of Proton-coupled amino acid transporter 1 |
|||||
|
Regulatory Variability Data of This DT |
|||||
|
(α) Microbiota Influence of Proton-coupled amino acid transporter 1 |
|||||
|
(β) Post-translational Modification of Proton-coupled amino acid transporter 1 |
|||||
|
(γ) Transcriptional Regulation of Proton-coupled amino acid transporter 1 |
|||||
|
(δ) Epigenetic Regulation of Proton-coupled amino acid transporter 1 |
|||||
|
(ε) Exogenous Modulation of Proton-coupled amino acid transporter 1 |
|||||
|
Structural Variability Data of This DT |
|||||
|
(β) Inter-species Structural Differences |
|||||
|
General Variability Data of This DT |
|||||
|
(α) Genetic Polymorphisms of Proton-coupled amino acid transporter 1 |
|||||
|
(β) Disease-specific Protein Abundances of Proton-coupled amino acid transporter 1 |
|||||
|
(γ) Species- and Tissue-specific DT Abundances |
|||||
| Molecular Transporting Profile of This DT | |||||
|
Full List of Drug(s) Transported by This DT |
|||||
|
Approved Drug |
Click to Show/Hide the Full List of Drug: 6 Drugs in Total | ||||
| Drug Name | Highest Status | Detail | Indication | ICD 11 | Ref |
|
Amino acids
|
Approved | Drug Info | Nutritional deficiency | 5B7Z | [1] |
|
Aminolevulinic acid
|
Approved | Drug Info | Photodynamic therapy | EK90.0 | [2] |
|
Cycloserine
|
Approved | Drug Info | Dementia | 6D8Z | [3] |
|
Glycine
|
Approved | Drug Info | Dietary shortage | 5B7Z | [4] |
|
L-proline
|
Approved | Drug Info | Dietary shortage | 5B7Z | [5] |
|
Vigabatrin
|
Approved | Drug Info | Infantile spasm | 8A62.0 | [6] |
|
Withdrawn, Discontinued or Preclinical Drug |
Click to Show/Hide the Full List of Drug: 1 Drugs in Total | ||||
| Drug Name | Highest Status | Detail | Indication | ICD 11 | Ref |
|
Gaboxadol
|
Discontinued in Phase 3 | Drug Info | Insomnia | 7A0Z | [7] |
|
Endogenous Metabolites (EMs) Handled by This DT |
|||||
|
Endogenous Metabolites (EMs) |
Click to Show/Hide the Full List of EMs: 1 EMs in Total | ||||
| EM Name | PubChem CID | Detail | Experimental Material | Ref | |
| Aminolevulinic acid | EM Info | Identified using COS-7 cells-PAT1 | [2] | ||
|
Drug-DT Affinity Assessed by Cell Line |
|||||
|
Approved Drug |
Click to Show/Hide the Full List of Drug: 4 Drugs in Total | ||||
| Drug Name | Highest Status | Detail | Cell Line | Affinity | Ref |
| Aminolevulinic acid | Approved | Drug Info | Monkey kidney fibroblast-like cell (COS)7-hPAT1 | Km =6800 microM | [2] |
| Aminolevulinic acid | Approved | Drug Info | Monkey kidney fibroblast-like cell (COS)7-hPAT1 | Km =6800 microM | [2] |
| Aminolevulinic acid | Approved | Drug Info | Monkey kidney fibroblast-like cell (COS)7-hPAT1 | Km =6800 microM | [2] |
| Vigabatrin | Approved | Drug Info | X.Laevis oocytes-hPAT1 | Km =5200 microM | [6] |
| References | |||||
| 1 | Substrate specificity of the amino acid transporter PAT1. Amino Acids. 2006 Sep;31(2):111-7. | ||||
| 2 | Delta-aminolevulinic acid is a substrate for the amino acid transporter SLC36A1 (hPAT1). Br J Pharmacol. 2010 Mar;159(6):1339-53. | ||||
| 3 | Indirect regulation of the intestinal H+-coupled amino acid transporter hPAT1 (SLC36A1). J Cell Physiol. 2005 Aug;204(2):604-13. | ||||
| 4 | Transport of amino acids and GABA analogues via the human proton-coupled amino acid transporter, hPAT1: characterization of conditions for affinity and transport experiments in Caco-2 cells. Eur J Pharm Sci. 2008 Sep 2;35(1-2):86-95. | ||||
| 5 | PAT1 (SLC36A1) shows nuclear localization and affects growth of smooth muscle cells from rats. Am J Physiol Endocrinol Metab. 2014 Jan 1;306(1):E65-74. | ||||
| 6 | Rectal absorption of vigabatrin, a substrate of the proton coupled amino acid transporter (PAT1, Slc36a1), in rats. Pharm Res. 2012 Apr;29(4):1134-42. | ||||
| 7 | Intestinal gaboxadol absorption via PAT1 (SLC36A1): modified absorption in vivo following co-administration of L-tryptophan. Br J Pharmacol. 2009 Aug;157(8):1380-9. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.